The Biologics Contract Development Market size is expected to reach USD 13.22 billion by 2030, according to a new study. The report gives a detailed insight into current market dynamics and provides an analysis of future market growth.
The market is being driven by factors such growing use of advanced technologies for biological production, increased R&D activities by pharmaceutical and biopharma businesses, and supportive regulations for clinical trials in developing nations. Biopharmaceutical CDMOs are adopting cutting-edge technology by investing time and capital to build differentiated capabilities.
China, India, and Korea remain the most popular regions for clinical research among developing nations. These nations' governments encourage outsourcing as it attracts foreign investment. Additionally, regulatory agencies in developing nations are aligning their policies with EMA and FDA standards speeding up the approval process.
During the COVID-19 pandemic, numerous CROs worked with biotechnology companies to do research and development on COVID-19 vaccines. The majority of clinical trials focused on developing new novel COVID-19 treatments. However, it is also projected that research will focus on cancer in the post-pandemic period due to rising cancer incidence.
Biologics Contract Development Market Report Highlights
The mammalian source segment became the dominant sector in 2021. This is due to the main benefit of using mammalian cells for protein expression and creating mammalian proteins with proper post-translational modifications that offer a native structure.
Many businesses are choosing to manufacture recombinant proteins and monoclonal antibodies; the process development segment is expected to grow in forthcoming years. Major biologics manufacturers provide process development to the client's business needs, regulatory constraints, and project timelines.
Due to the high need for cancer therapy, the oncology segment accounted for the greatest share, encouraging more company investments in R&D and outsourcing.
North America dominates the largest share owing to the increasing R&D investment and presence of local market players. Also, increasing outsourcing activities and the number of clinical trials in the region accelerate regional growth.
Major players operating in the industry include Abzena Ltd, AGC Biologics, Avid Bioservices, Inc; Bionova Scientific Inc, BioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH), Curia Global, Inc; KBI Biopharma, LakePharma, STC Biologics, Samsung Biologics, Thermo Fisher Scientific Inc., and WuXi Biologics.
The publisher has segmented the biologics contract development market report based on source, product service, indication, and region:
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...
The First Bancshares, Inc. ("FBMS" or "the Company") , holding company for The First Bank, (www.thefirstbank.com) reported today financial results for the quarter ended March 31, 2024.
Highlights for the Quarter:
Net income available to common...
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in thedevelopment oftherapeutics for age-related...
Alamos Gold Inc. ("Alamos" or the "Company") today reported its financial results for the quarter ended March 31, 2024. "We delivered another strong start to the year across a number of fronts, following a record performance in 2023. Costs...